BPA for jelmyto and zusduri
Active Awarded Last action
- Contract number
- 36E79726A0009
- Awardee
-
Urogen Pharma Inc. UEI L3U3BFJL3Z81
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 65% complete
- IDV ceiling
- $11,063,065.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Urogen Pharma Inc. has been awarded a single-award Blanket Purchase Agreement by the National Acquisition Center, the contracting office for the Department of Veterans Affairs, to supply specialized oncological pharmaceutical products to the VA healthcare system. The contract covers JELMYTO (mitomycin) and Zusduri (mitomycin), both antineoplastic antibiotic treatments, with JELMYTO indicated for low-grade upper tract urothelial cancer as the primary product offering. The BPA is valued at $11,063,065.00 with a period of performance from March 1, 2026 through February 28, 2027, and operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) with no set-aside designations applied, indicating full and open competition. Performance locations include Dublin, Ohio; La Vergne, Tennessee; and Princeton, New Jersey, demonstrating national distribution capabilities across the VA's healthcare network.
The BPA structure enables multiple Veterans Integrated Service Networks to issue delivery orders for these specialized cancer treatments without conducting individual full and open competitions for each procurement action, establishing pre-negotiated pricing and terms that support responsive procurement across geographically dispersed VA facilities. Historical delivery orders under predecessor contract vehicles have ranged from approximately $32,844 to $204,528, with all awards issued as firm fixed-price contracts. This indefinite delivery vehicle provides budgetary predictability through its established ceiling value while maintaining the operational flexibility required to meet clinical demand across the VA's network. The contract builds upon Urogen Pharma Inc.'s established role as a key supplier of innovative cancer pharmaceuticals to the VA system, with demonstrated performance since registration in the System for Award Management in March 2020.
Quick answers
Who was awarded contract 36E79726A0009?
36E79726A0009 was awarded to Urogen Pharma Inc. by National Acquisition Center (Headquarters) on March 1, 2026.
How much is contract 36E79726A0009 worth?
36E79726A0009's own ceiling is $11,063,065.
Who can order from contract 36E79726A0009?
36E79726A0009 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79726A0009 under another contract?
Yes. 36E79726A0009 is a blanket purchase agreement under 36F79721D0068, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79726A0009 competed?
The extent of competition for 36E79726A0009 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV